CombiGene has, by combining advancements in neuroscience and modern gene therapy, developed a treatment method which is shown to prevent epileptic seizures. It builds on research results from Lund University and the University of Copenhagen. CombiGene’s lead candidate, CG01, contains an AAV vector carrying the transgenes for the neurotransmitter Neuropeptide Y and one of its receptors, the G protein-coupled receptor Y2. Currently, the company is focusing on further developing this treatment for the benefit of epilepsy patients, but this method has the potential to be developed for other diseases. CombiGene is listed on AktieTorget and has its office at Medicon Village in Lund, Sweden.